BACKGROUND For lung adenocarcinoma with epidermal growth factor receptor(EGFR)gene mutation,small molecule tyrosine kinase inhibitors are more effective.Some patients could not obtain enough histological specimens for...BACKGROUND For lung adenocarcinoma with epidermal growth factor receptor(EGFR)gene mutation,small molecule tyrosine kinase inhibitors are more effective.Some patients could not obtain enough histological specimens for EGFR gene mutation detection.Specific imaging features can predict EGFR mutation status to a certain extent.AIM To assess the associations of EGFR mutations with high-resolution computerized tomography(HRCT)features in ground-glass nodular lung adenocarcinoma.METHODS This study retrospectively assessed patients with ground-glass nodular lung adenocarcinoma diagnosed between January 2011 and March 2017.EGFR gene mutations in exons 18-21 were detected.The patients were classified into mutant EGFR and wild-type groups,and general data and HRCT image characteristics were assessed.RESULTS Among 98 patients,31(31.6%)and 67(68.4%)had mutated and wild-type EGFR in exons 18-21,respectively.Gender,age,smoking history,location of lesions,morphology,edges,borders,pleural indentations,and associations of nodules with bronchus and blood vessels were comparable in both groups(all P>0.05).Patients with mutant EGFR had larger nodules than those with the wild-type(17.19±6.79 and 14.37±6.30 mm,respectively;P=0.047).Meanwhile,the vacuole/honeycomb sign was more frequent in the mutant EGFR group(P=0.011).The logistic regression prediction model included the combination of nodule size and vacuole/honeycomb sign(OR=1.120,95%CI:1.023-1.227,P=0.014)revealed a sensitivity of 83.9%,a specificity of 52.2%and an AUC of 0.698(95%CI:0.589-0.806;P=0.002).CONCLUSION Nodule size and vacuole/honeycomb features could independently predict EGFR mutation status in ground-glass nodular lung adenocarcinoma.展开更多
AIM:To investigate the correlation between human epidermal growth factor receptor(HER-2) protein expression and colorectal cancer(CRC) using a casecontrol study and meta-analysis.METHODS:Tumor tissue specimens from 16...AIM:To investigate the correlation between human epidermal growth factor receptor(HER-2) protein expression and colorectal cancer(CRC) using a casecontrol study and meta-analysis.METHODS:Tumor tissue specimens from 162 CRC patients were selected for the case group.Fifty cases were randomly selected,and normal CRC tissue at least 10 cm away from the tumor margins of these cases was used to generate the control group.The expression of the HER-2 protein in the 162 CRC tissue samples and the 50 adjacent normal mucosa tissue samples was detected via immunohistochemistry.The experimental data were analyzed using SPSS 18.0software,and R software version 3.1.0 was utilized for further verification.RESULTS:The expression of HER-2 protein in the 162 CRC tissue samples was significantly higher than in the normal tissue specimens.The data showed that the expression of HER-2 in CRC was related to the Dukes' stage,the depth of invasion and lymph node metastasis.The HER-2-positive patients had lower 3-and 5-year OS rates than the HER-2-negative patients,but there was no significant difference.However,there was a statistically significant difference in the 3- and5-year disease-free survival(DFS) rates of HER-2-positive and HER-2-negative patients.The results of the meta-analysis showed that the expression of HER-2in CRC patients was statistically significantly increased over that of healthy people.The 3-year DFS rate in HER-2-positive patients was markedly lower than that in HER-2-negative patients.CONCLUSION:Down-regulation of HER-2 expression might be a dependable strategy for CRC therapy.展开更多
Wound healing is a complex biologic event. Numerous growth factors are involved in the regulation of tissue repair and remodelling processes. In this study, several techniques were used to observe the effects of recom...Wound healing is a complex biologic event. Numerous growth factors are involved in the regulation of tissue repair and remodelling processes. In this study, several techniques were used to observe the effects of recombinant human epidermal growth factors (rh-EGF) on porcine partial-thickness burn wound healing. Healing rates of the burn wounds were quantitated by computer image analysis of the wound Pkotographs. Biopsies were taken for examining the cell DNA cycle by flow cytometry, and for observing the keratinocyte migration and degree of reepithelialization quantitated by anti-keratin antibodies. The results indicated that daily topical application of rh-EGF in suitable concentrations accelerated epithelial healing of partial-thickness burn wounds, and there was also a dose-dependent effect of rh-EGF on healing rates of the partial-thickness burn wounds.展开更多
Background： A number of studies have examined human epidermal growth factor receptor 2 （HER2） status in primary gastric cancer （GC） and associated metastasis, some showed their great concordance in FIER2 expressi...Background： A number of studies have examined human epidermal growth factor receptor 2 （HER2） status in primary gastric cancer （GC） and associated metastasis, some showed their great concordance in FIER2 expression, but others demonstrated notable discordance. There is still little consensus on HER2 discordance, therefore, a systematic review and meta-analysis was conducted to assess the status on HER2 discordance between primary GC and its paired metastasis. Methods： PubMed, EMBASE, ASCO and The Cochrane Library were searched for studies that explored the concordance between primary tumor and metastasis in patients with GC up to 10 March, 2014. Data of discordance of HER2 between primary GC and corresponding metastasis were extracted from the publications and random-effects models were used to estimate pooled discordance proportions. Results： Eighteen articles including 1,867 patients were included for the meta-analysis in accordance with the selection criteria. Pooled discordance proportions were 7% [95% confidence interval （CI）： 5-10%] for HER2 status. Pooled proportions of tumors shifting from positive to negative and from negative to positive were 17% （95% CI： 7-29%） and 4% （95% CI： 2-6%） respectively. No publication bias was found in the meta-analysis. Conclusions： The discordance of HER2 status is not rare in primary and metastatic GC through our metaanalysis. Prospective studies are needed to testify the clinical significance of the discordance of HER2 status.展开更多
Objective：The epidermal growth factor receptor （EGFR） inhibitors monoclonal antibodies （MoAbs） have already shown the therapeutic effectiveness in patients with metastatic colorectal cancer （mCRC）.But many pati...Objective：The epidermal growth factor receptor （EGFR） inhibitors monoclonal antibodies （MoAbs） have already shown the therapeutic effectiveness in patients with metastatic colorectal cancer （mCRC）.But many patients resist to the treatment.The aim of this meta-analysis was to assess EGFR gene copy number （GCN） as a candidate predictive biomarker for resistance to anti-EGFR MoAbs in mCRC treatment.Methods：Systematic computerized searches of the PubMed,EMBase and Cochrane Library were performed.The primary endpoint was objective response rate （ORR）.The second endpoints included progression-free survival （PFS）,and overall survival （OS）.The pooled odd ratio （OR） and pooled sensitivity,specificity,and summary receiver operator characteristic （SROC） for ORR were estimated.The pooled hazard ratios （HR） for PFS and OS were also calculated.Results：Fourteen studies with 1,021 patients were included.Increased EGFR GCN was associated with increased ORR （OR=6.905; 95％ CI：4.489-10.620）.It was also found in wild-type KRAS mCRC patients,with the pooled OR of 8.133 （95 ％ CI：4.316-15.326）.GCN has medium value for predicting ORR,with the pooled sensitivity of 0.79 （95％ CI：0.73-0.84）,the pooled specificity of 0.59 （95％ CI：0.55-0.62）.In wildtype KRAS mCRC patients,the sensitivity and the specificity were 0.80 （95％ CI：0.70-0.87） and 0.60 （95％CI：0.53-0.66）,respectively.Increased EGFR GCN was associated with increased PFS （HR=0.557; 95％ CI：0.382-0.732） and OS （HR=0.579; 95％ CI：0.422-0.737）.Conclusions：This meta-analysis suggests that EGFR GCN represents a predictive biomarker for tumor response in mCRC patients treated with MoAbs regardless of KRAS mutation.mCRC patients with increased EGFR GCN are more likely to have a better response,PFS,and OS when treated with cetuximab or panitumumab.展开更多
Objective Epidermal growth factor receptor(EGFR) and vascular endothelial growth factor(VEGF) inhibitors are two targeted therapies for metastatic colorectal cancer(mCRC). However, few studies have focused on the safe...Objective Epidermal growth factor receptor(EGFR) and vascular endothelial growth factor(VEGF) inhibitors are two targeted therapies for metastatic colorectal cancer(mCRC). However, few studies have focused on the safety and efficacy of combined targeted therapy against those of a single inhibition therapy of EFGR or VEGF. This meta-analysis aimed to compare the anti-tumor activity of the combined inhibition therapy and single inhibition therapy in patients with mCRC. Methods We searched PubMed, Medline, the Cochrane library, Embase, and annual meeting proceedings for relevant clinical trials. Objective response rate(ORR), progression-free survival(PFS), overall survival(OS), and adverse events were extracted and calculated.Results Nine trials comprising 3977 patients were selected for the analysis. The combined inhibition therapy showed a 3.7% improvement in ORR compared with single inhibition, and this difference was statistically significant [hazard ratio(HR) = 1.33; 95% confidence interval(CI), 1.01–1.74; P = 0.04]. Subgroup analysis showed that the combined EGFR and VEGF inhibitor therapy had an 11.65% improvement in ORR compared with VEGF inhibitor therapy(OR = 2.14; 95% CI, 1.34–3.40; P = 0.001). EGFR and VEGF inhibitor therapy and chemotherapy had an 18.08% improvement in ORR compared with chemotherapy(OR = 2.21; 95% CI, 1.05–4.64; P = 0.04). Moreover, EGFR and VEGF inhibitor therapy significantly improved PFS compared with VEGF inhibitor therapy(OR = 0.82; 95% CI, 0.69–0.97; P = 0.02). VEGF inhibitor therapy and chemotherapy significantly improved PFS compared with EGFR and VEGF inhibitor therapy and chemotherapy(OR = 1.20; 95% CI, 1.11–1.30; P = 0.00). In addition, EGFR and VEGF inhibitor therapy showed improved OS compared with VEGF inhibitor therapy(HR = 0.78, 95% CI: 0.65–0.94; P = 0.008). Finally, the combined inhibition therapy showed an obviously increased risk of cutaneous and mucosal effects(RR = 6.45; 95% CI: 2.71–15.36; P < 0.01), diarrhea/abdominal pain(RR = 1.97; 95% CI: 1.45–2.68; P < 0.01), fatigue/asthenia(RR = 1.60; 95% CI: 1.10–2.32; P = 0.01), dehydration or electrolyte disturbance(RR = 2.78; 95% CI: 1.48–5.21; P < 0.01), nail disorder(RR = 8.23; 95% CI: 1.52–44.57; P = 0.01), and dizziness/headache(RR = 3.43; 95% CI: 1.89–6.23; P < 0.01) compared with single inhibition therapy.Conclusion Compared with single inhibition therapy, the combined inhibition therapy significantly improved ORR, PFS, and OS in the treatment of mCRC patients. Compared with a single-targeted agent, the combined therapy of anti-EGFR and anti-VEGF drug provided an efficacy advantage, although it led to greater toxicity.展开更多
Objective:The aim of this study is to evaluate the efficacy of Traditional Chinese Medicine(TCM)in the treatment of rash caused by epidermal growth factor receptor inhibitors(EGFRIs).Materials and Methods:Foreign lang...Objective:The aim of this study is to evaluate the efficacy of Traditional Chinese Medicine(TCM)in the treatment of rash caused by epidermal growth factor receptor inhibitors(EGFRIs).Materials and Methods:Foreign language database(such as Pub Med,Web of Science,Cochrane Library,EMBASE)and Chinese language database(such as China National Knowledge Infrastructure,VIP Database for Chinese Technical Periodicals[VIP],Wangfang,CBM disc)were searched for all trials of TCM in the treatment of rash caused by EGFRIs until January of 2019.We also looked through the references of relevant studies to supplement additional trials.The SPSS 25.0 was used for statistics of TCM with high frequency,and Review Manager 5.3 was used for meta-analysis.Results:A total of 22 studies were included in the study.We selected TCM whose frequency were>3.0%.They were Lonicera japonica(金银花),Licorice Roots Northwest Origin(生甘草),Cortex Dictamni(白鲜皮),Radix Sophorae Flavescentis(苦参),Schizonepeta(荆芥),Saposhnikovia Divaricate(防风).The meta-analysis revealed that the efficacy of TCM in treating EGFRIs-related rash was better than that of Western medicine or none.Conclusions:TCM could significantly relieve rash caused by EGFRIs,which is worth popularizing.Moreover,the mechanism deserves to be further explored.展开更多
目的分析酪氨酸激酶抑制剂(TKIs)治疗人表皮生长因子受体2(HER2)阳性乳腺癌的研究现状、热点和发展趋势。方法在Web of Science核心合集数据库中检索TKIs治疗HER2阳性乳腺癌的相关文献,使用CiteSpace 6.1.R3软件对发文作者、国家/地区...目的分析酪氨酸激酶抑制剂(TKIs)治疗人表皮生长因子受体2(HER2)阳性乳腺癌的研究现状、热点和发展趋势。方法在Web of Science核心合集数据库中检索TKIs治疗HER2阳性乳腺癌的相关文献,使用CiteSpace 6.1.R3软件对发文作者、国家/地区、机构、学科领域、期刊、关键词进行可视化分析。结果共纳入732篇文献,发文量呈逐年上升趋势,以美国发文最多(中心度0.10),我国发文量排第2位(中心度0.05)。发文量和被引频次最多的作者分别是澳大利亚圣文森特大学医院的Crown和美国加州大学洛杉矶分校的Slamon;发文量最多的机构是美国得克萨斯大学安德森癌症中心,最多的期刊是美国Journal of Clinical Oncology;研究热点主要集中在HER2阳性乳腺癌治疗药物、TKIs作用受体、TKIs作用机制、HER2阳性乳腺癌脑转移、TKIs临床研究5个方面;前沿领域和发展趋势主要为TKIs与其他药物或治疗手段联用以增强靶向性并降低毒副作用。结论TKIs治疗HER2阳性乳腺癌的研究受到国内外学者的重视。我国学者和研究团队未来需要加强合作交流,可从TKIs单用及联合用药治疗HER2阳性乳腺癌的疗效及安全性方面加强与其他国家的合作。展开更多
目的分析2010—2021年糖尿病溃疡(DU)发病机制的研究现状、热点及发展趋势。方法检索2010—2021年Web of Science核心合集数据库发表的有关DU发病机制的文献,应用CiteSpace软件,对文献的数据进行计量和可视化分析。结果共纳入706篇文献,...目的分析2010—2021年糖尿病溃疡(DU)发病机制的研究现状、热点及发展趋势。方法检索2010—2021年Web of Science核心合集数据库发表的有关DU发病机制的文献,应用CiteSpace软件,对文献的数据进行计量和可视化分析。结果共纳入706篇文献,2010—2021年DU发病机制的研究发文量整体呈增长趋势;发文量最高的国家、机构、作者分别为美国、迈阿密大学、Aristidis V;知识基础涉及负压伤口治疗、糖尿病伤口治疗、细胞机制等内容。结论近十年来DU发病机制的研究热度呈上升趋势,伤口愈合、基因表达、生长因子为研究热点,组织修复、细胞凋亡、炎症为未来研究的趋势。展开更多
基金by the Zhejiang Province Traditional Chinese Medicine Science and Technology Plan-Zhejiang Province Traditional Chinese Medicine Project for Traditional Chinese Medicine Scientific Research(2020)(Class B),No.2020ZB117。
文摘BACKGROUND For lung adenocarcinoma with epidermal growth factor receptor(EGFR)gene mutation,small molecule tyrosine kinase inhibitors are more effective.Some patients could not obtain enough histological specimens for EGFR gene mutation detection.Specific imaging features can predict EGFR mutation status to a certain extent.AIM To assess the associations of EGFR mutations with high-resolution computerized tomography(HRCT)features in ground-glass nodular lung adenocarcinoma.METHODS This study retrospectively assessed patients with ground-glass nodular lung adenocarcinoma diagnosed between January 2011 and March 2017.EGFR gene mutations in exons 18-21 were detected.The patients were classified into mutant EGFR and wild-type groups,and general data and HRCT image characteristics were assessed.RESULTS Among 98 patients,31(31.6%)and 67(68.4%)had mutated and wild-type EGFR in exons 18-21,respectively.Gender,age,smoking history,location of lesions,morphology,edges,borders,pleural indentations,and associations of nodules with bronchus and blood vessels were comparable in both groups(all P>0.05).Patients with mutant EGFR had larger nodules than those with the wild-type(17.19±6.79 and 14.37±6.30 mm,respectively;P=0.047).Meanwhile,the vacuole/honeycomb sign was more frequent in the mutant EGFR group(P=0.011).The logistic regression prediction model included the combination of nodule size and vacuole/honeycomb sign(OR=1.120,95%CI:1.023-1.227,P=0.014)revealed a sensitivity of 83.9%,a specificity of 52.2%and an AUC of 0.698(95%CI:0.589-0.806;P=0.002).CONCLUSION Nodule size and vacuole/honeycomb features could independently predict EGFR mutation status in ground-glass nodular lung adenocarcinoma.
文摘AIM:To investigate the correlation between human epidermal growth factor receptor(HER-2) protein expression and colorectal cancer(CRC) using a casecontrol study and meta-analysis.METHODS:Tumor tissue specimens from 162 CRC patients were selected for the case group.Fifty cases were randomly selected,and normal CRC tissue at least 10 cm away from the tumor margins of these cases was used to generate the control group.The expression of the HER-2 protein in the 162 CRC tissue samples and the 50 adjacent normal mucosa tissue samples was detected via immunohistochemistry.The experimental data were analyzed using SPSS 18.0software,and R software version 3.1.0 was utilized for further verification.RESULTS:The expression of HER-2 protein in the 162 CRC tissue samples was significantly higher than in the normal tissue specimens.The data showed that the expression of HER-2 in CRC was related to the Dukes' stage,the depth of invasion and lymph node metastasis.The HER-2-positive patients had lower 3-and 5-year OS rates than the HER-2-negative patients,but there was no significant difference.However,there was a statistically significant difference in the 3- and5-year disease-free survival(DFS) rates of HER-2-positive and HER-2-negative patients.The results of the meta-analysis showed that the expression of HER-2in CRC patients was statistically significantly increased over that of healthy people.The 3-year DFS rate in HER-2-positive patients was markedly lower than that in HER-2-negative patients.CONCLUSION:Down-regulation of HER-2 expression might be a dependable strategy for CRC therapy.
文摘Wound healing is a complex biologic event. Numerous growth factors are involved in the regulation of tissue repair and remodelling processes. In this study, several techniques were used to observe the effects of recombinant human epidermal growth factors (rh-EGF) on porcine partial-thickness burn wound healing. Healing rates of the burn wounds were quantitated by computer image analysis of the wound Pkotographs. Biopsies were taken for examining the cell DNA cycle by flow cytometry, and for observing the keratinocyte migration and degree of reepithelialization quantitated by anti-keratin antibodies. The results indicated that daily topical application of rh-EGF in suitable concentrations accelerated epithelial healing of partial-thickness burn wounds, and there was also a dose-dependent effect of rh-EGF on healing rates of the partial-thickness burn wounds.
基金supported by National Natural Science Foundation of China(No.81172110)National High Technology Research and Development Program(No. 2012AA 02A 504)+2 种基金Beijing Municipal Science & Technology Commission Program(No.Z11110706730000)Beijing Natural Science Foundation(7142034)China Postdoctoral Science Foundation(2013M530494)
文摘Background： A number of studies have examined human epidermal growth factor receptor 2 （HER2） status in primary gastric cancer （GC） and associated metastasis, some showed their great concordance in FIER2 expression, but others demonstrated notable discordance. There is still little consensus on HER2 discordance, therefore, a systematic review and meta-analysis was conducted to assess the status on HER2 discordance between primary GC and its paired metastasis. Methods： PubMed, EMBASE, ASCO and The Cochrane Library were searched for studies that explored the concordance between primary tumor and metastasis in patients with GC up to 10 March, 2014. Data of discordance of HER2 between primary GC and corresponding metastasis were extracted from the publications and random-effects models were used to estimate pooled discordance proportions. Results： Eighteen articles including 1,867 patients were included for the meta-analysis in accordance with the selection criteria. Pooled discordance proportions were 7% [95% confidence interval （CI）： 5-10%] for HER2 status. Pooled proportions of tumors shifting from positive to negative and from negative to positive were 17% （95% CI： 7-29%） and 4% （95% CI： 2-6%） respectively. No publication bias was found in the meta-analysis. Conclusions： The discordance of HER2 status is not rare in primary and metastatic GC through our metaanalysis. Prospective studies are needed to testify the clinical significance of the discordance of HER2 status.
文摘Objective：The epidermal growth factor receptor （EGFR） inhibitors monoclonal antibodies （MoAbs） have already shown the therapeutic effectiveness in patients with metastatic colorectal cancer （mCRC）.But many patients resist to the treatment.The aim of this meta-analysis was to assess EGFR gene copy number （GCN） as a candidate predictive biomarker for resistance to anti-EGFR MoAbs in mCRC treatment.Methods：Systematic computerized searches of the PubMed,EMBase and Cochrane Library were performed.The primary endpoint was objective response rate （ORR）.The second endpoints included progression-free survival （PFS）,and overall survival （OS）.The pooled odd ratio （OR） and pooled sensitivity,specificity,and summary receiver operator characteristic （SROC） for ORR were estimated.The pooled hazard ratios （HR） for PFS and OS were also calculated.Results：Fourteen studies with 1,021 patients were included.Increased EGFR GCN was associated with increased ORR （OR=6.905; 95％ CI：4.489-10.620）.It was also found in wild-type KRAS mCRC patients,with the pooled OR of 8.133 （95 ％ CI：4.316-15.326）.GCN has medium value for predicting ORR,with the pooled sensitivity of 0.79 （95％ CI：0.73-0.84）,the pooled specificity of 0.59 （95％ CI：0.55-0.62）.In wildtype KRAS mCRC patients,the sensitivity and the specificity were 0.80 （95％ CI：0.70-0.87） and 0.60 （95％CI：0.53-0.66）,respectively.Increased EGFR GCN was associated with increased PFS （HR=0.557; 95％ CI：0.382-0.732） and OS （HR=0.579; 95％ CI：0.422-0.737）.Conclusions：This meta-analysis suggests that EGFR GCN represents a predictive biomarker for tumor response in mCRC patients treated with MoAbs regardless of KRAS mutation.mCRC patients with increased EGFR GCN are more likely to have a better response,PFS,and OS when treated with cetuximab or panitumumab.
基金Supported by the grants of the National Natural Science Foundation of China(No.81372396)Natural Science Foundation of Jiangsu Province(No.BK20141016 and BK20141017)
文摘Objective Epidermal growth factor receptor(EGFR) and vascular endothelial growth factor(VEGF) inhibitors are two targeted therapies for metastatic colorectal cancer(mCRC). However, few studies have focused on the safety and efficacy of combined targeted therapy against those of a single inhibition therapy of EFGR or VEGF. This meta-analysis aimed to compare the anti-tumor activity of the combined inhibition therapy and single inhibition therapy in patients with mCRC. Methods We searched PubMed, Medline, the Cochrane library, Embase, and annual meeting proceedings for relevant clinical trials. Objective response rate(ORR), progression-free survival(PFS), overall survival(OS), and adverse events were extracted and calculated.Results Nine trials comprising 3977 patients were selected for the analysis. The combined inhibition therapy showed a 3.7% improvement in ORR compared with single inhibition, and this difference was statistically significant [hazard ratio(HR) = 1.33; 95% confidence interval(CI), 1.01–1.74; P = 0.04]. Subgroup analysis showed that the combined EGFR and VEGF inhibitor therapy had an 11.65% improvement in ORR compared with VEGF inhibitor therapy(OR = 2.14; 95% CI, 1.34–3.40; P = 0.001). EGFR and VEGF inhibitor therapy and chemotherapy had an 18.08% improvement in ORR compared with chemotherapy(OR = 2.21; 95% CI, 1.05–4.64; P = 0.04). Moreover, EGFR and VEGF inhibitor therapy significantly improved PFS compared with VEGF inhibitor therapy(OR = 0.82; 95% CI, 0.69–0.97; P = 0.02). VEGF inhibitor therapy and chemotherapy significantly improved PFS compared with EGFR and VEGF inhibitor therapy and chemotherapy(OR = 1.20; 95% CI, 1.11–1.30; P = 0.00). In addition, EGFR and VEGF inhibitor therapy showed improved OS compared with VEGF inhibitor therapy(HR = 0.78, 95% CI: 0.65–0.94; P = 0.008). Finally, the combined inhibition therapy showed an obviously increased risk of cutaneous and mucosal effects(RR = 6.45; 95% CI: 2.71–15.36; P < 0.01), diarrhea/abdominal pain(RR = 1.97; 95% CI: 1.45–2.68; P < 0.01), fatigue/asthenia(RR = 1.60; 95% CI: 1.10–2.32; P = 0.01), dehydration or electrolyte disturbance(RR = 2.78; 95% CI: 1.48–5.21; P < 0.01), nail disorder(RR = 8.23; 95% CI: 1.52–44.57; P = 0.01), and dizziness/headache(RR = 3.43; 95% CI: 1.89–6.23; P < 0.01) compared with single inhibition therapy.Conclusion Compared with single inhibition therapy, the combined inhibition therapy significantly improved ORR, PFS, and OS in the treatment of mCRC patients. Compared with a single-targeted agent, the combined therapy of anti-EGFR and anti-VEGF drug provided an efficacy advantage, although it led to greater toxicity.
文摘Objective:The aim of this study is to evaluate the efficacy of Traditional Chinese Medicine(TCM)in the treatment of rash caused by epidermal growth factor receptor inhibitors(EGFRIs).Materials and Methods:Foreign language database(such as Pub Med,Web of Science,Cochrane Library,EMBASE)and Chinese language database(such as China National Knowledge Infrastructure,VIP Database for Chinese Technical Periodicals[VIP],Wangfang,CBM disc)were searched for all trials of TCM in the treatment of rash caused by EGFRIs until January of 2019.We also looked through the references of relevant studies to supplement additional trials.The SPSS 25.0 was used for statistics of TCM with high frequency,and Review Manager 5.3 was used for meta-analysis.Results:A total of 22 studies were included in the study.We selected TCM whose frequency were>3.0%.They were Lonicera japonica(金银花),Licorice Roots Northwest Origin(生甘草),Cortex Dictamni(白鲜皮),Radix Sophorae Flavescentis(苦参),Schizonepeta(荆芥),Saposhnikovia Divaricate(防风).The meta-analysis revealed that the efficacy of TCM in treating EGFRIs-related rash was better than that of Western medicine or none.Conclusions:TCM could significantly relieve rash caused by EGFRIs,which is worth popularizing.Moreover,the mechanism deserves to be further explored.
文摘目的分析酪氨酸激酶抑制剂(TKIs)治疗人表皮生长因子受体2(HER2)阳性乳腺癌的研究现状、热点和发展趋势。方法在Web of Science核心合集数据库中检索TKIs治疗HER2阳性乳腺癌的相关文献,使用CiteSpace 6.1.R3软件对发文作者、国家/地区、机构、学科领域、期刊、关键词进行可视化分析。结果共纳入732篇文献,发文量呈逐年上升趋势,以美国发文最多(中心度0.10),我国发文量排第2位(中心度0.05)。发文量和被引频次最多的作者分别是澳大利亚圣文森特大学医院的Crown和美国加州大学洛杉矶分校的Slamon;发文量最多的机构是美国得克萨斯大学安德森癌症中心,最多的期刊是美国Journal of Clinical Oncology;研究热点主要集中在HER2阳性乳腺癌治疗药物、TKIs作用受体、TKIs作用机制、HER2阳性乳腺癌脑转移、TKIs临床研究5个方面;前沿领域和发展趋势主要为TKIs与其他药物或治疗手段联用以增强靶向性并降低毒副作用。结论TKIs治疗HER2阳性乳腺癌的研究受到国内外学者的重视。我国学者和研究团队未来需要加强合作交流,可从TKIs单用及联合用药治疗HER2阳性乳腺癌的疗效及安全性方面加强与其他国家的合作。
文摘目的分析2010—2021年糖尿病溃疡(DU)发病机制的研究现状、热点及发展趋势。方法检索2010—2021年Web of Science核心合集数据库发表的有关DU发病机制的文献,应用CiteSpace软件,对文献的数据进行计量和可视化分析。结果共纳入706篇文献,2010—2021年DU发病机制的研究发文量整体呈增长趋势;发文量最高的国家、机构、作者分别为美国、迈阿密大学、Aristidis V;知识基础涉及负压伤口治疗、糖尿病伤口治疗、细胞机制等内容。结论近十年来DU发病机制的研究热度呈上升趋势,伤口愈合、基因表达、生长因子为研究热点,组织修复、细胞凋亡、炎症为未来研究的趋势。
